Page 40 - IFIA_Magazine_No11

| IFIA Magazine - Mar ch 2021
IfIa becomes partner of
the Iam at pharma &
bIotech Ip semInar
usa 2020
International Federation of Inventors’
Associations (IFIA) becomes the partner of
the Pharma & Biotech IP USA 2020.
The life sciences are in a period of dramatic
change and innovation. Developments in
new technologies, such as cell therapies and
gene editing, are challenging traditional IP
strategies and business models.
IAM’s fourth annual Pharma and Biotech
IP will bring together leading in-house
practitioners and expert counsel to discuss
next-generation strategies for protecting
and exploiting cutting-edge innovation.
The host
IAM is the leading intelligence platform for
the global IP market. Our unrivaled coverage
and in-depth analysis of key sectors give our
clients critical information to enable them to
40
maximize the value of their IP assets.
Our unique and timely intelligence,
analysis and data service informs high-
level corporate decision making, while our
extensive connections with senior operators
in the corporate, legal, policymaking, and
investment worlds provide a clear line of
sight into market developments before they
are widely known.
IAM offers global coverage of the IP value
creation environment. Our worldwide team
of reporters, researchers, and analysts
provide an unmatched understanding of
local markets in North America, Europe, and
Asia to ensure that IAM is the first to provide
the analysis that matters.
The life sciences are seeing developments
in new technologies and undergoing a
period of dramatic change and innovation,
all of which are challenging traditional IP
strategies and business models.
IAM’s inaugural Pharma & Biotech IP USA
heads to Boston after four successful years
in Europe to bring together leading in-house
practitioners and expert counsel to explore
next-generation strategies for protecting
and exploiting cutting-edge innovation